Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFRvIII CAR-T (DCTY0801) in Recurrent Glioblastoma
NCT05802693Phase 1Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of DCTY0801 in glioblastoma (GBM), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Incidence of adverse events at 15 years and Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
DCTY0801
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05802693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802693.